Pharmaceuticals

End Stage Renal Disease (ESRD) Drug Global Forecast: Market to Scale Up to $304.07 Billion by 2030 at 15.5% CAGR

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the end stage renal disease (esrd) drug market from 2026–2035 with trusted insights from The Business Research Company

What is the expected shift in the End Stage Renal Disease (ESRD) Drug Market’s size between 2026 and 2030?

The end stage renal disease (esrd) drug market size has shown rapid expansion in recent years. It is forecast to grow from $148.55 billion in 2025 to $171.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. This historical growth can be attributed to the rising prevalence of ckd, increased awareness of esrd, an uptick in dialysis centers, advancements in renal therapeutics, and supportive government healthcare initiatives.

The end stage renal disease (esrd) drug market is anticipated to experience substantial growth in the forthcoming years. It is forecasted to reach $304.07 billion by 2030, growing at a compound annual growth rate (CAGR) of 15.5%. Factors contributing to this growth during the projected period include the evolution of precision medicine, broader availability of homecare dialysis, the integration of AI in patient monitoring, increased investments in esrd R&D, and the expanding use of combination therapies. Significant trends for the forecast duration encompass personalized esrd drug treatments, solutions for home-based dialysis, the integration of telemedicine into CKD management, enhanced drug formulations addressing secondary complications, and a continued increase in the adoption of combination therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp

Which Drivers Are Shaping Strategic Decisions In The End Stage Renal Disease (ESRD) Drug Market?

The future expansion of the end-stage renal disease (ESRD) drug market is anticipated to be driven by an increase in obesity and diabetes cases. Obesity refers to an abnormal or excessive accumulation of fat that poses health risks. In contrast, diabetes is a chronic condition occurring when the pancreas produces insufficient insulin or the body cannot efficiently utilize the insulin it produces. For patients with renal disease, managing fluid and electrolyte levels, blood pressure, and eliminating waste products through dialysis can enhance overall health and well-being, potentially leading to weight reduction and improved blood sugar control. For instance, in 2023, the World Obesity Federation, a non-profit membership organization, estimated that by 2035, the economic cost of overweight and obesity would reach US$ 4.32 trillion annually, equivalent to nearly 3% of globa. Furthermore, in June 2024, the National Health Service, a UK-based government department, indicated that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels, though not high enough to be classified as diabetes) in 2023, marking an 18% increase from 3,065,825 cases in 2022. Therefore, the rising incidence of obesity and diabetes will fuel the market for end-stage renal disease (ESRD) drugs.

What Segment Categories Are Covered In The End Stage Renal Disease (ESRD) Drug Market?

The end stage renal disease (esrd) drug market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol

3) By Sterols: Ergocalciferol, Cholecalciferol

4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate

5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate

6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents

What Trends Are Projected To Support The Growth Of The End Stage Renal Disease (ESRD) Drug Market?

Companies operating within the end-stage renal disease (ESRD) drug market are primarily focused on obtaining product approvals, such as for Jardiance, to enhance their market revenues. Empagliflozin is a medication intended to assist individuals with type 2 diabetes and to lessen the risk of cardiovascular problems in type 2 diabetes patients who also suffer from heart failure or cardiovascular disease. For example, in September 2023, Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, secured FDA approval for Jardiance. Jardiance has received authorization for multiple uses, including reducing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression, as well as mitigating the risk of a sustained decline in estimated glomerular filtration rate (eGFR) in adults with heart failure. Jardiance functions as a sodium-glucose cotransporter 2 (SGLT2) inhibitor and is not advised for patients with type 1 diabetes or those with an eGFR less than 20 ml/min/1.73 m.

Which Key Players Are Driving Competition In The End Stage Renal Disease (ESRD) Drug Market?

Major companies operating in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Which Region Is Projected To Lead The End Stage Renal Disease (ESRD) Drug Market During The Forecast Period?

North America was the largest region in the end stage renal disease (ESRD) drug market in 2025. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized End Stage Renal Disease (ESRD) Drug Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9437&type=smp

Browse Through More Reports Similar to the Global End Stage Renal Disease (ESRD) Drug Market 2026, By The Business Research Company

End Stage Renal Disease Esrd Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/end-stage-renal-disease-esrd-drug-global-market-report

Late Stage Chronic Kidney Disease Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Kidney Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795